Is BMY a good stock to buy?
Bristol-Myers Squibb Company · end-of-day data as of Nov 13, 2026
- P/E vs sector-56.3%
- FCF yield+7.2%
- Trendbullish
- MAs4 of 4
- MA20×50Golden 1d ago
- MACD0.13
- Sector▲ +15.9%
- Earnings in83d
- P/E14.1x
- RSI56
- Support-0.1%
- Resistance+3.4%
- Off 52w high-7.6%
- Volume0.9x
- Bollingerupper half
- News
- P/E vs own-5.0%
- ConsensusHold · 28
- PT$66.53 +4.9%
- 52w range$45–$69
- ATR+2.8%
- Off ATH-22.1%
- Insiders-$678K
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Bristol-Myers Squibb a good stock to buy?
Bristol-Myers Squibb is strong on 2 of the 5 questions about the business; weak on advantage. The price is about usual: 14.1 times its earnings, near its 3-year median of 16.3 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage easy to copy
- Economics profits growing
- Execution delivers
- Fragility some risks
- Price about usual
BMY sales growth revenue growth
+1%a year, for the last 3 yearsBristol-Myers Squibb's sales grew 1% a year for 3 years, to $48.2B in fiscal 2025.
BMY analysts' forecast revenue estimates
+4%the sales they expect next fiscal year, on the lastAnalysts expect Bristol-Myers Squibb's sales to grow 4% to $50.15B in fiscal 2026 (19 analysts).
BMY competitors
pretickt analysis+4%its sales in 12 months, on a year before
Bristol-Myers Squibb's sales grew 4% in the 12 months to Sep 30, 2026, faster than Pfizer (+1%), slower than Amgen (+8%), Gilead (+7%) and Merck (+5%).
BMY customers' spending
pretickt analysis+23%what its customers invest, on a year before
Cencora, Cardinal Health and McKesson, customers of Bristol-Myers Squibb, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.
BMY sales by business revenue by segment
30%of its sales from EliquisEliquis brought Bristol-Myers Squibb 30% of its sales in fiscal 2025; Opdivo 21%.
BMY margin on each sale gross margin
69%left after making the productBristol-Myers Squibb kept 69% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 75%.
BMY cash generated free cash flow
$9.29Bcash left after investing, last 12 monthsBristol-Myers Squibb generated $9.29B of free cash flow in the 12 months to Sep 30, 2026, about as much as its reported profit.
BMY earnings vs estimates
8 of 8quarters above the analysts' estimateBristol-Myers Squibb beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 29, 2026.
BMY insider selling
-$2.53Msold, net, by its executives in 12 monthsBristol-Myers Squibb's executives and directors sold a net $2.53M of shares in the 12 months to Nov 13, 2026; none bought.
BMY number of employees
-5%fewer people in a yearBristol-Myers Squibb had 32,500 employees at the end of fiscal 2025, 5% fewer than a year before.
BMY CEO pay
$21.88Mfor fiscal 2025, 73% of it in stock and optionsBristol-Myers Squibb paid its CEO $21.88M for fiscal 2025, 73% of it in stock and options.
BMY financial health Altman Z-score
2.7Altman Z-score, safe above 3Bristol-Myers Squibb's Altman Z-score is 2.7 (Nov 13, 2026), between 1.8 and 3, the grey zone.
BMY quality checks Piotroski score
6 of 9checks passedBristol-Myers Squibb passes 6 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt, new shares and gross margin.
BMY price vs profit P/E ratio
14.1×a year's earningsBristol-Myers Squibb's P/E ratio is 14.1 (Nov 13, 2026), near its 3-year median of 16.3.
BMY price vs competitors
pretickt analysis14.1×a year's earnings, against its competitorsInvestors pay 14.1 times Bristol-Myers Squibb's earnings (Nov 13, 2026), less than for Merck (152.3), Pfizer (41.5) or Amgen (27.0).
BMY analysts' target price target
+5%to their average targetAnalysts' average price target for Bristol-Myers Squibb is $66.53, 5% above the Nov 13, 2026 close of $63.43.
BMY analyst ratings, 90 days
pretickt analysisLeerink Partnersdowngrade
In the 90 days to Nov 13, 2026, Leerink Partners downgraded Bristol-Myers Squibb.
BMY growth priced in fair value
pretickt analysis+2%a year, for ten years, to be worth the priceAt $63.43 a share, Bristol-Myers Squibb's free cash flow must grow about 2% a year for ten years to be worth the price (Nov 13, 2026).
What is Bristol-Myers Squibb's P/E ratio?
Bristol-Myers Squibb's P/E ratio is 14.1 (Nov 13, 2026), near its 3-year median of 16.3. Investors pay 14.1 times Bristol-Myers Squibb's earnings (Nov 13, 2026), less than for Merck (152.3), Pfizer (41.5) or Amgen (27.0).
Who are Bristol-Myers Squibb's biggest competitors?
pretickt compares Bristol-Myers Squibb with Pfizer, Gilead, Amgen and Merck. Bristol-Myers Squibb's sales grew 4% in the 12 months to Sep 30, 2026, faster than Pfizer (+1%), slower than Amgen (+8%), Gilead (+7%) and Merck (+5%).
Are insiders selling Bristol-Myers Squibb stock?
Bristol-Myers Squibb's executives and directors sold a net $2.53M of shares in the 12 months to Nov 13, 2026; none bought.
How does Bristol-Myers Squibb make money?
Eliquis brought Bristol-Myers Squibb 30% of its sales in fiscal 2025; Opdivo 21%.
Who owns Bristol-Myers Squibb stock?
2,636 institutions hold 85% of Bristol-Myers Squibb's shares (Jun 30, 2026); BlackRock, Vanguard and State Street added shares that quarter.
How many employees does Bristol-Myers Squibb have?
Bristol-Myers Squibb had 32,500 employees at the end of fiscal 2025, 5% fewer than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.